Everything below concerns metabolic research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Macrophage activation syndrome (MAS) is a severe, potentially life-threatening complication that can occur in patients with the systemic subtype of JIA. MAS involves uncontrolled activation of the immune system, which can present with a sepsis-like picture of fever, rash, enlarged liver and spleen, enlarged lymph nodes and cardiorespiratory compromise.
===== Gravimetric method ===== The increased mass of the MOF due to the stored hydrogen is directly calculated by a sensitive microbalance. Due to buoyancy, the detected mass of adsorbed hydrogen decreases again when a sufficiently high pressure is applied to the system because the density of the surrounding gaseous hydrogen becomes more and more important at higher pressures. Thus, this "weight loss" has to be corrected using the volume of the MOF's frame and the density of hydrogen.
==== Buffer regions and midpoints ==== A titration curve for a diprotic acid contains two midpoints where pH=pKa. Since there are two different Ka values, the first midpoint occurs at pH=pKa1 and the second one occurs at pH=pKa2. Each segment of the curve that contains a midpoint at its center is called the buffer region. Because the buffer regions consist of the acid and its conjugate base, it can resist pH changes when base is added until the next equivalent points.
Sources: en.wikipedia.org
Soul music became the popular music of young adults, therefore, we changed with the times. Now since I played trumpet as a youth in high school, it was natural to play dual harmonies with Frank on many of these songs. This was due to the horn charts that were inherent in the music of that time period." With a change in style, came a change in venues, as The Sinners began expanding their base, performing at Italia East (where their second record was made), Bob's Inn in Brewerton, The Turn On, The Red Dog Saloon, Manlius, NY, and more S.U. (Syracuse University) frat parties. "We also played an O.C.C. (Onondaga Community College) commencement" According to Ron Lauback "I got up in line next to the chancellor of the college, and shook hands with the graduating students and wished them good luck." The Saint and the Sinners continued until summer 1968, when Tommy Forrest left to re-join The Monterays (Frank Sgroi would resurface with The Seven). After The Saint and the Sinners folded Ron and George Day briefly worked with The Monterays before forming Airborne (1969). This group featured a female lead singer (Karen Franklin) and was even more soul based, but Ron inexplicably left music a year later to devote more time to his family and career. Airborne did record a number of demos that were remastered and given limited release on the 3 Records label in 2000.
It is thought that there have been at least 30 El Niño events between 1900 and 2024, with the 1982–83, 1997–98 and 2014–16 events among the strongest on record. Since 2000, El Niño events have been observed in 2002–03, 2004–05, 2006–07, 2009–10, 2014–16, 2018–19, 2023–24, and 2026. Major ENSO events were recorded in the years 1790–93, 1828, 1876–78, 1891, 1925–26, 1972–73, 1982–83, 1997–98, 2014–16, 2023–24 and 2026–27. During strong El Niño episodes, a secondary peak in sea surface temperature across the far eastern equatorial Pacific Ocean sometimes follows the initial peak.
This is normally a "prompt" process, but sometimes does not rapidly reach to the nuclear ground state, in which case a metastable isomer has formed. This usually occurs as a spin isomer when the formation of an intermediate excited state has a spin far different from that of the ground state. Gamma-ray emission is hindered if the spin of the post-emission state differs greatly from that of the emitting state, and if the excitation energy is low; such excited states will generally have long lives and be considered metastable. After fission, several of the fission fragments may be produced in a metastable isomeric state, after their prompt de-excitation. At the end of this process, the nuclei can populate both the ground and the isomeric states. If the half-life of an isomer is long enough, it is possible to measure its production rate, and comparing it to that of the ground state gives the so-called isomeric yield ratio.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.